Analysts expect American Renal Associates Holdings Inc (NYSE:ARA) to report earnings of $0.13 per share for the current fiscal quarter, Zacks reports. Two analysts have made estimates for American Renal Associates’ earnings, with the highest EPS estimate coming in at $0.13 and the lowest estimate coming in at $0.12. American Renal Associates posted earnings per share of $0.18 in the same quarter last year, which indicates a negative year over year growth rate of 27.8%. The company is scheduled to issue its next earnings report on Tuesday, March 5th.
According to Zacks, analysts expect that American Renal Associates will report full-year earnings of $0.60 per share for the current fiscal year, with EPS estimates ranging from $0.56 to $0.65. For the next fiscal year, analysts anticipate that the business will report earnings of $0.64 per share, with EPS estimates ranging from $0.56 to $0.70. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow American Renal Associates.
American Renal Associates (NYSE:ARA) last posted its quarterly earnings results on Thursday, November 8th. The company reported $0.19 EPS for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.06. The firm had revenue of $211.02 million for the quarter, compared to analysts’ expectations of $217.15 million. American Renal Associates had a negative net margin of 1.11% and a positive return on equity of 19.60%. The business’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.19 earnings per share.
NYSE ARA opened at $17.50 on Monday. The company has a current ratio of 1.07, a quick ratio of 1.04 and a debt-to-equity ratio of 5.30. American Renal Associates has a 12 month low of $9.91 and a 12 month high of $24.07. The stock has a market capitalization of $667.52 million, a PE ratio of 28.69, a P/E/G ratio of 3.63 and a beta of 2.09.
Several large investors have recently added to or reduced their stakes in ARA. Rhumbline Advisers bought a new stake in shares of American Renal Associates in the 2nd quarter valued at about $195,000. Macquarie Group Ltd. raised its position in shares of American Renal Associates by 1,867.7% in the 2nd quarter. Macquarie Group Ltd. now owns 20,700 shares of the company’s stock valued at $326,000 after purchasing an additional 19,648 shares during the last quarter. Paloma Partners Management Co purchased a new position in shares of American Renal Associates in the 2nd quarter valued at approximately $356,000. Russell Investments Group Ltd. purchased a new position in shares of American Renal Associates in the 2nd quarter valued at approximately $405,000. Finally, Engineers Gate Manager LP raised its position in shares of American Renal Associates by 74.4% in the 3rd quarter. Engineers Gate Manager LP now owns 22,892 shares of the company’s stock valued at $496,000 after purchasing an additional 9,764 shares during the last quarter. Institutional investors and hedge funds own 92.67% of the company’s stock.
American Renal Associates Company Profile
American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.
Featured Article: Conference Calls and Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.